Skip to content

IEMbase 0474: GALK1-related galactokinase deficiency

Scope

Field Value
IEMbase ID 474
Nosology 3.1.03.01
Gene GALK1
External IDs OMIM:230200; ORPHA:79237
Generated mapping UNMAPPED; low candidate Galactosemia.yaml
Candidate DisMech targets Galactosemia.yaml#Galactokinase Deficiency
Review date 2026-07-07

IEMbase phenotype signal

IEMbase represents autosomal recessive GALK1-related galactokinase deficiency, also called galactosemia type 2. Biochemical rows include decreased galactokinase activity in fibroblasts and red blood cells, normal erythrocyte GALT activity, increased plasma and urine galactose, increased urine galactitol, urine reducing substances, normal erythrocyte galactose-1-phosphate, and neonatal or infantile plasma glucose that is low-to-normal. Clinical rows include cataract and pseudotumor cerebri. IEMbase records galactose-restricted and lactose-free diet as a nutritional treatment.

DisMech phenotype coverage

Galactosemia.yaml#Galactokinase Deficiency is the correct local target. The local Galactosemia entry explicitly includes a galactokinase deficiency subtype caused by GALK1 deficiency, with decreased galactokinase activity, disrupted galactose catabolism, excess galactose conversion to galactitol, lens toxicity, and cataract.

Concordance and completeness

Judgement: false negative; resolve IEMbase 474 to Galactosemia.yaml#Galactokinase Deficiency.

The local target captures the entity, gene, Leloir-pathway step, galactitol-lens mechanism, and cataract endpoint. IEMbase adds useful biochemical and clinical prompts not yet fully represented locally, including normal GALT activity, normal galactose-1-phosphate, explicit urine/plasma galactose rows, galactose-restricted diet, and pseudotumor cerebri.

Curation actions

  • Map IEMbase 474 to Galactosemia.yaml#Galactokinase Deficiency.
  • If importing IEMbase-derived prompts, verify diet response, normal erythrocyte GALT activity, normal erythrocyte galactose-1-phosphate, urinary reducing substances, and pseudotumor cerebri against source evidence.